JointHealth™ express January 4, 2012
Reminder: Let BC PharmaCare hear “Your Voice”
Do you live with osteoporosis, care for someone with the disease, or does your organization represent people with osteoporosis? There is one more week to provide feedback to British Columbia’s Ministry of Health about zoledronic acid (Aclasta®), for the treatment of osteoporosis in postmenopausal women, via a website called Your Voice.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
To view the information sheet for zoledronic acid: click here
For the patients and caregivers survey: click here
For the patient group survey: click here. (Patient groups are required to register their name with the Ministry of Health before making their submission.)
There is one week left to submit input on zoledronic acid. The deadline is midnight on January 12, 2012.
Reminder: Let BC PharmaCare hear “Your Voice”
Do you live with osteoporosis, care for someone with the disease, or does your organization represent people with osteoporosis? There is one more week to provide feedback to British Columbia’s Ministry of Health about zoledronic acid (Aclasta®), for the treatment of osteoporosis in postmenopausal women, via a website called Your Voice.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
To view the information sheet for zoledronic acid: click here
For the patients and caregivers survey: click here
For the patient group survey: click here. (Patient groups are required to register their name with the Ministry of Health before making their submission.)
There is one week left to submit input on zoledronic acid. The deadline is midnight on January 12, 2012.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.